Please use this identifier to cite or link to this item: https://doi.org/10.1097/FTD.0000000000000298
Title: Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers
Authors: Lee, JW
Pussegoda, K
Rassekh, SR
Monzon, JG
Liu, G
Hwang, S
Bhavsar, AP
Pritchard, S
Ross, CJ
Amstutz, U
Carleton, BC
Hayden, MR
MacLeod, S
Smith, A 
Brunham, L 
Aminkeng, F 
Shear, NH
Koren, G
Ito, S
Madadi, P
Rieder, MJ
Kim, R
Maher, M
Flockhart, D
Keywords: Antineoplastic Agents
Cisplatin
Genetic Markers
Hearing Loss
Humans
Pharmacogenetics
Polymorphism, Genetic
Issue Date: 1-Aug-2016
Publisher: Ovid Technologies (Wolters Kluwer Health)
Citation: Lee, JW, Pussegoda, K, Rassekh, SR, Monzon, JG, Liu, G, Hwang, S, Bhavsar, AP, Pritchard, S, Ross, CJ, Amstutz, U, Carleton, BC, Hayden, MR, MacLeod, S, Smith, A, Brunham, L, Aminkeng, F, Shear, NH, Koren, G, Ito, S, Madadi, P, Rieder, MJ, Kim, R, Maher, M, Flockhart, D (2016-08-01). Clinical Practice Recommendations for the Management and Prevention of Cisplatin-Induced Hearing Loss Using Pharmacogenetic Markers. Therapeutic Drug Monitoring 38 (4) : 423-431. ScholarBank@NUS Repository. https://doi.org/10.1097/FTD.0000000000000298
Abstract: Currently no pharmacogenomics-based criteria exist to guide clinicians in identifying individuals who are at risk of hearing loss from cisplatin-based chemotherapy. This review summarizes findings from pharmacogenomic studies that report genetic polymorphisms associated with cisplatin-induced hearing loss and aims to (1) provide up-to-date information on new developments in the field, (2) provide recommendations for the use of pharmacogenetic testing in the prevention, assessment, and management of cisplatin-induced hearing loss in children and adults, and (3) identify knowledge gaps to direct and prioritize future research. These practice recommendations for pharmacogenetic testing in the context of cisplatin-induced hearing loss reflect a review and evaluation of recent literature, and are designed to assist clinicians in providing optimal clinical care for patients receiving cisplatin-based chemotherapy.
Source Title: Therapeutic Drug Monitoring
URI: https://scholarbank.nus.edu.sg/handle/10635/235097
ISSN: 0163-4356
1536-3694
DOI: 10.1097/FTD.0000000000000298
Appears in Collections:Staff Publications
Elements

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
02_Cisplatin-Main Text.pdf236.21 kBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.